Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations

Molecular Cancer Therapeutics

Volumn 3, Issue 9, 2004, Pages 1127-1135

  Bacolod, Manny D ^a   Johnson, Stewart P ^a   Pegg, Anthony E ^b   Dolan, M Eileen ^c   Moschel, Robert C ^d   Bullock, Nancy S ^a   Fang, Qingming ^b   Colvin, O Michael ^a   Modrich, Paul ^a   Bigner, Darell D ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ALKYLATING AGENT; CARMUSTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER RESISTANCE; CLONAL VARIATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG BINDING; DRUG MECHANISM; ENZYME STRUCTURE; GENE EXPRESSION; GENE MUTATION; IN VITRO STUDY; MEDULLOBLASTOMA; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SARCOMA CELL; STRUCTURE ANALYSIS; WILD TYPE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; DEOXYGUANOSINE; DRUG RESISTANCE, NEOPLASM; GUANINE; HUMANS; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMORPHISM, GENETIC;

EID: 4644297350     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994;20:111-20.
2. Lemoine A, Lucas C, Ings RM. Metabolism of the chloroethylnitrosoureas. Xenobiotica 1991;21:775-91.
3. 1-bis[2-chloroethyl]-N-nitrosourea). Biochem Biophys Res Commun 1981;100:351-7.
4. 1-deoxyguanosinyl]ethane in DNA treated with N,N′-bis[2-chloroethyl]-N-nitrosourea. Cancer Res 1982;42:3102-5.
5. 6-alkylguanine-DNA transferases. Mutat Res 1990;233:165-75.
6. Ali-Osman F, Caughlan J, Gray GS. Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-l-nitrosourea after in vitro reaction with glutathione. Cancer Res 1989;49:5954-8.
7. Allan JIM, Engelward BP, Dreslin AJ, Wyatt MID, Tomasz M, Samson LD. Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Cancer Res 1998;58:3965-73.
8. Xu Y, Hansen WK, Rosenquist TA, Williams DA, Limp-Foster M, Kelley MR. Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N′-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and α -hOgg1: implications for protective gene therapy applications. J Pharmacol Exp Ther 2001; 296:825-31.
9. Ali-Osman F, Rairkar A, Young P. Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. Cancer Biochem Biophys 1995; 14:231-41.
10. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990; 87:5368-72.
11. 6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl -1-nitrosourea. Cancer Commun 1990; 2:371-7.
12. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997;3:837-47.
13. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.
14. (6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002;20:2277-83,
15. 6-benzylguanine. Biochem J 2000;347:519-26.
16. Bacolod MD, Johnson SP, Ali-Osman F, et al. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Mol Cancer Ther 2002;1:727-36.
17. Friedman HS, Colvin OM, Kaufmann SH, et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1992;52:5373-8.
18. 6-benzylguanine. Cancer Res 1996;56:5571-5.
19. 6-alkylguanine-DNA alkyltransferase. Biochemistry 1998; 37:12489-95.
20. 6-benzylguanine. Biochem J 2000; 347:527-34.
21. 6-benzylguanine. Cancer Res 1998; 58:1936-45.
22. 6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. Cancer Res 1990;50:58-61.
23. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000;36:2294-300.
24. 6-alkylguanine-DNA alkyltransferase: identification of a missense variation in the active site region. Pharmacogenetics 1999;9:81-7.
25. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
26. Goldie JH, Coldman AJ. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses. Cancer Invest 1985;3:553-64.
27. Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res 2002;511:45-62.
28. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
29. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Potter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 1999;450:197-204.
30. 6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 1998;17:845-51.
31. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGFβ1: a paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-8.
32. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 1993;90:6424-8.
33. Glaab WE, Tindall KR. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 1997;18:1-8.
34. Ohzeki S, Tachibana A, Tatsumi K, Kato T. Spectra of spontaneous mutations at the hprt locus in colorectal carcinoma cell lines defective in mismatch repair. Carcinogenesis 1997;18:1127-33.
35. Glaab WE, Risinger JI, Umar A, Barrett JC, Kunkel TA, Tindall KR. Cellular resistance and hypermutability in mismatch repair-deficient human cancer cell lines following treatment with methyl methanesulfonate. Mutat Res 1998;398:197-207.
36. de las Alas MM, Aebi S, Fink D, Howell SB, Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 1997;89:1537-41.
37. Chen WD, Eshleman JR, Aminoshariae MR, et al. Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. J Natl Cancer Inst 2000;92:480-5.
38. Liu L, Schwartz S, Davis BM, Gerson SL. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res 2002;62:3070-6.
39. Minnick DT, Veigl ML, Sedwick WD. Mutational specificity of 1,3-bis-(2-chloroethyl)-1-nitrosourea in a Chinese hamster ovary cell line. Cancer Res 1992;52:4688-95.
40. 6-alkylguanine-DNA alkyltransferase. Cancer Res 1993; 53:997-1003.
41. Dickerson RE. Base sequence and helix structure variation in B and A DNA. J Mol Biol 1983;166:419-41.
42. Wilbley JE, Pegg AE, Moody PC. Crystal structure of the human O(6)-alkylguanine-DNA alkyltransferase. Nucleic Acids Res 2000;28: 393-401.
43. Daniels DS, Mol CD, Arvai AS, Kanugula S, Pegg AE, Tainer JA. Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding. EMBO J 2000;19:1719-30.
44. Encell LP, Coates MM, Loeb LA. Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis. Cancer Res 1998;58:1013-20.
45. Loktionova NA, Pegg AE. Interaction of mammalian O(6)-alkylguanine-DNA alkyltransferases with O(6)-benzylguanine. Biochem Pharmacol 2002;63:1431-42.
46. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:339-42.
47. 6-benzylguanine. Biochem J 2000;347:519-26.
48. Holmes J Jr, Clark S, Modrich P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci U S A 1990;87:5837-41.